Dotinurad
Dotinurad is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against solute carrier family 22 member 12.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperuricemia | D033461 | — | — | 2 | 4 | 5 | 1 | — | 11 |
| Gout | D006073 | EFO_0004274 | M10 | 2 | 2 | 4 | 2 | — | 9 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | 2 | — | — | — | 10 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dotinurad |
| INN | dotinurad |
| Description | Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia. It was developed by Fuji Yakuhin and approved for use in Japan in 2020. The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe.
|
| Classification | Small molecule |
| Drug class | urate transporter inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(c1cc(Cl)c(O)c(Cl)c1)N1CS(=O)(=O)c2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 1285572-51-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594446 |
| ChEBI ID | — |
| PubChem CID | 51349053 |
| DrugBank | DB16145 |
| UNII ID | 305EB53128 (ChemIDplus, GSRS) |
Target
Agency Approved
SLC22A12
SLC22A12
Organism
Homo sapiens
Gene name
SLC22A12
Gene synonyms
OATL4, URAT1
NCBI Gene ID
Protein name
solute carrier family 22 member 12
Protein synonyms
Organic anion transporter 4-like protein, Renal-specific transporter, RST, solute carrier family 22 (organic anion/cation transporter), member 12, solute carrier family 22 (organic anion/urate transporter), member 12, URAT1, Urate anion exchanger 1, urate anion transporter 1, urate transporter 1, Urate:anion antiporter SLC22A12
Uniprot ID
Mouse ortholog
—
—
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 185 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use